Abridge picks up strategic investment from Eli Lilly, expands payer, research workflows

Since launching eight years ago with an ambient medical transcription tool, Abridge has set is sights more broadly on building out a full-scale AI clinical assistant. | Abridge secured a strategic investment from Eli Lilly and unveiled a major platform expansion to integrate payer and life sciences workflows. Described as an "AI-native clinician intelligence platform," Abridge says it now connects care delivery, payment and evidence-based treatment.